Dr. David John Kuter, MD

Dr. Kuter practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Kuter's NPI, 1457342024, was assigned on November 2, 2005. Dr. Kuter graduated from Harvard Medical School in 1978. Dr. Kuter holds Massachusetts license 47157.

Dr. Kuter's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Kuter's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Kuter is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Kuter to 3 more hospitals, 1 community health center and 1 medical group, each named with a free account. Dr. Kuter's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kuter practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Kuter's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Kuter is licensed in Massachusetts.

CMS data shows 1,028 Medicare services from Dr. Kuter across 3 procedure codes in 2024, for 350 Medicare patients. Medicare paid $67,222 for them.

CMS counts 350 Medicare patients who saw Dr. Kuter in 2024. The largest group is 75 to 84, with 167 patients. 66% of them have high blood pressure, and 65% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kuter's median patient age at 76, with 57% women.

In 2024, Dr. Kuter wrote 615 Medicare Part D claims for 154 patients. 32% of them were for generic drugs. CMS names the drug for 557 of them, across 10 drugs with 11 or more claims each, at $3,575,915 in total drug cost. In 2023, CMS named 568 claims across 10 drugs.

Dr. Kuter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kuter as offering telehealth.

Dmand AI links 108 papers to Dr. Kuter, published from 2009 to 2025. 2018 was the busiest year, with 12. The most frequent topics are Purpura, Thrombocytopenic, Idiopathic, Thrombopoietin and Platelet Count. Dr. Kuter has published most often in Am J Hematol. Dr. Kuter's most frequent co-authors are Hanny Toban Al-Samkari, MD, James B. Bussel, MD and Catherine M. Broome, MD.

Dmand AI links Dr. Kuter to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Purpura, Thrombocytopenic, Idiopathic, Purpura, Thrombocytopenic and Anemia, Hemolytic, Autoimmune. Bioverativ, a Sanofi company sponsors the most, 2. Open Payments lists research payments to Dr. Kuter that name 5 trials.

CMS Open Payments shows 457 general payments to Dr. Kuter from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Amgen Inc. paid the most, $265,197. It also lists 84 research payments totaling $348,056 from 2018 to 2025, naming 5 clinical trials.

Dr. Kuter graduated from Harvard Medical School in 1978.